NUVA earnings

–U.S. Cervical continues to deliver greater than 20% year-over-year growth––International net sales grew 6.8% as reported and 9.8% on a constant currency basis– SAN DIEGO, Aug. 2, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Net sales were $317.8 million, a 2.4% increase as reported and a 3.1% increase on a constant currency basi

SAN DIEGO, July 24, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that it will release its second quarter 2023 results on Wednesday, August 2, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, August 2, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the second quarter of 2023. The dial-in numbers are 1-877-407-9039 for domestic calle

–Continued above-market worldwide net sales growth of 5.8% as reported and 7.7% on a constant currency basis––U.S. cervical delivers sixth consecutive quarter of greater than 20% growth, driven by C360 and the Simplify Cervical Disc– SAN DIEGO, May 10, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Highlights Net sales were $307.7 million, a

SAN DIEGO, May 4, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its first quarter 2023 results on Wednesday, May 10, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, May 10, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the first quarter of 2023. The dial-in numbers are 1-877-300-8521 for domestic callers a

– Full-year 2022 net sales grew 5.5% as reported, 8.5% on a constant currency basis – – Continued strong international growth in 2022 – – U.S. cervical delivers growth of greater than 20% year-over-year driven by C360 – – 2,000+ Pulse cases performed worldwide since commercial launch – SAN DIEGO, Feb. 22, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter and full year ended December 31, 2022.

Capitalizes on complementary global commercial organizations and accelerates Globus Medical's and NuVasive's globalization strategies to increase customer reach and deepen surgeon relationships Brings together innovative technologies to create comprehensive procedural solutions offering to better support surgeons, healthcare providers and patients Leverages shared commitment to innovation to further both companies' efforts to address the full continuum of care and help solve unmet clinical needs Expands operational excellence capabilities to further serve and enable the combined commercial organizations to better support customers Strong financial profile and value creation opportunity Compa

SAN DIEGO, Jan. 30, 2023 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its fourth quarter and full-year 2022 results on Wednesday, February 22, 2023, after the close of the market. NuVasive will hold a conference call on Wednesday, February 22, 2023, at 1:30 p.m. PT / 4:30 p.m. ET to discuss the results of its financial performance for the fourth quarter and full year ended December 31, 2022. The

– Net sales grew 9.0% as reported, 12.9% on a constant currency basis – – C360 portfolio delivers record quarter in cervical net sales – – Company updates full-year 2022 guidance – SAN DIEGO, Nov. 9, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended September 30, 2022. Third Quarter 2022 Net sales were $295.3 million, a 9.0% increase as reported and a 12.9% increase on a constant

SAN DIEGO, Oct. 25, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its third quarter financial results on Wednesday, November 9, 2022, after the market close. NuVasive will hold a conference call on Wednesday, November 9, 2022, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the third quarter ended September 30, 2022. The dial-in numbers are 1-877-300-85

–Strong year-over-year net sales growth, driven by new product introductions– –Company reiterates full-year guidance range for reported year-over-year net sales growth of 6%–8%– –Company updates full-year guidance range for GAAP diluted EPS; maintains prior non-GAAP diluted EPS range provided May 4, 2022– SAN DIEGO, Aug. 3, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2022.

SAN DIEGO, July 18, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its second quarter results on Wednesday, August 3, 2022, after the close of the market. NuVasive will hold a conference call on Wednesday, August 3, 2022, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the second quarter ended June 30, 2022. The dial-in numbers are 1-877-407-9039 for dom

–  Strong year-over-year net sales growth, driven by new product introductions and International sales ––  Company raises lower end of full-year 2022 financial guidance range – SAN DIEGO, May 4, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended March 31, 2022. First Quarter 2022 Net sales were $290.8 million, a 7.2% increase as reported and a 9.1% increase on a constant currency b

SAN DIEGO, April 20, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its first quarter results on Wednesday, May 4, 2022, after the close of the market. NuVasive will hold a conference call on Wednesday, May 4, 2022, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the first quarter ended March 31, 2022. The dial-in numbers are 1-877-407-9039 for domestic

SAN DIEGO, Feb. 23, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter and full year ended December 31, 2021. Fourth Quarter 2021 Net sales were $302.1 million, a 3.5% increase as reported and a 4.5% increase on a constant currency basis, compared to the prior year period; GAAP operating margin of (9.4%); Non-GAAP operating margin of 12.9%; and GAAP diluted loss per share of $0.71; Non-G

SAN DIEGO, Feb. 8, 2022 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its fourth quarter and full year 2021 results on Wednesday, February 23, 2022, after the close of the market. NuVasive will hold a conference call on Wednesday, February 23, 2022, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the fourth quarter and full year ended December 31, 2021. The

SAN DIEGO, Nov. 9, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended September 30, 2021. Third Quarter 2021 Net sales decreased 8.3% to $270.8 million, on a reported and constant currency basis, compared to the prior year period; GAAP operating margin of (2.4%); Non-GAAP operating margin of 11.2%; and GAAP diluted loss per share of $0.42; Non-GAAP diluted earnings per share of $0.

SAN DIEGO, Oct. 25, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today the Company will release its third quarter 2021 earnings results on Tuesday, November 9, 2021, after the close of the market. NuVasive will hold a conference call on Tuesday, November 9, 2021, at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results of its financial performance for the third quarter of 2021. The dial-in numbers are 1-877-407-9039 for dom

SAN DIEGO, July 28, 2021 /PRNewswire/ -- NuVasive, Inc. (NASDAQ:NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced financial results for the quarter ended June 30, 2021. Second Quarter 2021 Highlights Net sales increased 44.8% to $294.8 million, or 43.3% on a constant currency basis; GAAP operating margin of 3.6%; Non-GAAP operating margin of 13.9%; and GAAP diluted earnings per share of $0.03; Non-GAAP diluted earnings per share of $0.60."NuVasive continued to se